ArticlePloS one2025
Melanoma in Peru: 1000 patients and 10 years of experience.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpidemiological studies identify characteristics of melanoma based on race and ethnic groups. Previous reports have revealed that the Hispanic/Latino population with melanoma has different characteristics compared to other races. We aimed to describe the sociodemographic, clinicopathological features, and long-term outcomes such as event-free survival (EFS) and overall survival (OS) Peruvian population with melanoma.
methodsWe conducted a retrospective cohort study of new cases diagnosed and treated at a single tertiary institution from 2010 to 2019. Survival analysis included patients with stages I-IV. Multivariable Cox Regression analysis was used to assess prognostic factors.
resultsA total of 1136 patients were included, the median age at diagnosis was 63 years old (6-97 years), the majority were males (51.5%), resided in a non-metropolitan area (77.7%), had a primary lesion in lower extremities (75.5%), ulceration (52.4%), and acral lentiginous was the most common histological subtype (38.1%). The mean Breslow was 8.88, and 6.62 number of mitoses per mm. Stage T3-4 was present in 70.4%, while Stage III was the most frequent AJCC Stage (36.5%). Regarding adjuvant therapy, 13.4% received chemotherapy, 3.6% radiotherapy, and 13.6% interferon. No patients received immunotherapy. At 5-year follow-up, the EFS was 20%, while the OS was 36%. Prognostic factors of worse EFS were greater age (HR = 1.020), male sex (HR = 1.369), greater mitotic rates (HR = 1.012), ulceration (HR = 1.564), positive lymph nodes (HR = 2.58), while primary lesion in upper extremities (HR = 0.518) was associated to better EFS. Prognostic factors of worse OS were greater age (HR = 1.024), greater mitotic rate (HR = 1.013), ulceration (HR = 1.72), and positive lymph nodes (HR = 3.231).
conclusionsThe sociodemographic features of Peruvian patients with melanoma are different from other populations. There were higher stages without access to immunotherapy, therefore EFS and OS rates were worse than international reports, while prognostic factors were similar. Urgent healthcare policy changes are needed as is access to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.